6+ hour, 50+ min ago  (256+ words) Suven Life Sciences announced positive Phase-2b trial results for its depression drug candidate, Ropanicant (SUVN-911). The trial met its primary endpoint, showing statistically significant improvement in patients with Major Depressive Disorder (MDD). This success paves the way for planning Phase-3 trials....